Contrave highlights of prescribing information, Food and Drug Administration (2024) Wegovy highlights of prescribing information, Food and Drug Administration (2024) Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet (2010) Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity and Metabolism (2022) Label: Contrave extended-release naltrexone hydrochloride and bupropion hydrochloride tablet, extended release, DailyMed (2024) Label: Wegovy- semaglutide injection, solution, DailyMed (2024) Update on FDAs ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for Type 2 diabetes and obesity, Food and Drug Administration (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Memberships Specials at IntraVenous Solutions As part of our commitment to affordable care, were thrilled to run specials on our wellness and restoration services throughout the year
For less than a single year of wegovy
Many patients taking Ozempic (semaglutide) for type 2 diabetes wonder whether this medication affects their sleep
Shes not worried about measuring out the water or mixing the drug
Cardiovascular disease Several GLP-1 RAs have demonstrated cardioprotective benefits, including reductions in MACE, heart failure hospitalizations, and progression of atherosclerosis